INmune Bio Inc (NASDAQ: INMB) open the trading on Thursday, with a bit cautious approach as it glided -4.27% to $2.24, before settling in for the price of $2.34 at the close. Taking a more long-term approach, INMB posted a 52-week range of $1.89-$11.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -23.07%. Meanwhile, its Annual Earning per share during the time was -23.07%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 30.94%. This publicly-traded company’s shares outstanding now amounts to $22.93 million, simultaneously with a float of $18.90 million. The organization now has a market capitalization sitting at $59.55 million.
INmune Bio Inc (INMB) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. INmune Bio Inc’s current insider ownership accounts for 28.90%, in contrast to 27.86% institutional ownership. According to the most recent insider trade that took place on Sep 30 ’24, this organization’s Chief Financial Officer bought 10,000 shares at the rate of 5.29, making the entire transaction reach 52,868 in total value, affecting insider ownership by 1,285,869. Preceding that transaction, on Sep 12 ’24, Company’s President and CEO bought 15,380 for 6.38, making the whole transaction’s value amount to 98,048. This particular insider is now the holder of 1,554,106 in total.
INmune Bio Inc (INMB) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
INmune Bio Inc’s EPS increase for this current 12-month fiscal period is 30.94% and is forecasted to reach -1.32 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 47.53% through the next 5 years, which can be compared against the -23.07% growth it accomplished over the previous five years trading on the market.
INmune Bio Inc (NASDAQ: INMB) Trading Performance Indicators
Let’s observe the current performance indicators for INmune Bio Inc (INMB). It’s Quick Ratio in the last reported quarter now stands at 2.64. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1191.00.
In the same vein, INMB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.95, a figure that is expected to reach -0.38 in the next quarter, and analysts are predicting that it will be -1.32 at the market close of one year from today.
